Novo Nordisk A/S ($NVO) Stock Forecast: Up 5.1% Today

What is Novo Nordisk A/S?

Novo Nordisk (NVO) is a pharmaceutical company focusing on treatments for serious metabolic diseases. The stock showed strong bullish movement today.

Why is Novo Nordisk A/S going up?

NVO stock is up 5.1% on Dec 10, 2025 19:40

• The bullish movement in Novo Nordisk's stock could be linked to the completion of its acquisition of Akero Therapeutics, which is slated to expand its portfolio and potential for growth.
• Investor interest may have been piqued by the reevaluation of NVO's valuation following a significant share price decline earlier this year.
• Encouraging developments concerning Novo Nordisk's key products, such as promising sales projections for Wegovy and progress in amycretin trials, likely bolstered investor confidence in the company's future outlook.
• Novo Nordisk's legal actions to prevent Sun Pharma from introducing a generic version of its weight-loss medication ahead of an impending patent expiration showcases the company's commitment to safeguarding its market share and intellectual property, potentially impacting the bullish market activity.

NVO Price Chart

NVO Technical Analysis

NVO News

Skip The Market Darling Eli Lilly; Buy The Underdog Novo Nordisk (NYSE:NVO)

This article argues that Novo Nordisk (NVO) is undervalued compared to its Big Pharma peers, including Eli Lilly (LLY), despite its strong growth and profitability. The author attributes NVO's recent market cap decline to exaggerated adverse events and highlights its industry-leading margins, cash flow, and promising oral GLP-1 candidates. While acknowledging competitive and patent risks, the author rates NVO a "modest BUY" due to its low valuation and suggests Eli Lilly is a "cautious HOLD" as its stock is priced for perfection.

https://seekingalpha.com/article/4852027-skip-the-market-darling-eli-lilly-buy-the-underdog-novo-nordisk

Novo Nordisk has completed its acquisition of Akero Therapeutics

Novo Nordisk has completed its acquisition of Akero Therapeutics for $54 per share in cash, plus a Contingent Value Right (CVR) of an additional $6 per share upon US regulatory approval of Akero's lead candidate, EFX. Akero is now a wholly-owned subsidiary of Novo Nordisk, and its common stock will no longer be listed on the Nasdaq Global Select Market. Akero Therapeutics focuses on treatments for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH), with its lead candidate efruxifermin (EFX) currently in Phase 3 clinical studies.

https://finance.yahoo.com/news/novo-nordisk-completed-acquisition-akero-135100343.html

Novo Nordisk (NYSE:NVO): Reassessing Valuation After This Year’s Sharp Share Price Pullback

Novo Nordisk (NVO) shares have experienced a sharp pullback this year, with a year-to-date return of minus 46.6 percent, despite continued growth in revenue and net income. This has led to the stock trading at a significant discount to analyst targets, suggesting it may be undervalued. The current narrative indicates a fair value more than double its last close, driven by disciplined growth, strong margins, and innovation, though risks like GLP-1 competition and aggressive US drug pricing exist.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nysenvo-reassessing-valuation-after-this-years

Key facts: Wegovy sales projected at $11.9B; Ozempic reaches $898.5M in China; Novo Nordisk advances amycretin trials

Novo Nordisk's Wegovy is projected to achieve $11.9 billion in global sales this year, with a significant portion of US prescriptions being cash purchases. Its Ozempic drug has already reached $898.5 million in sales in Greater China, pre-empting a competitor's launch. Additionally, Novo Nordisk is advancing trials for its weight-loss drug amycretin, which has shown promising results in initial studies.

https://www.tradingview.com/news/tradingview:e3f873a479a8f:0-key-facts-wegovy-sales-projected-at-11-9b-ozempic-reaches-898-5m-in-china-novo-nordisk-advances-amycretin-trials/

Novo Nordisk moves Delhi HC to block Sun Pharma as weight loss drug patent expiry looms

Novo Nordisk has initiated legal action in the Delhi High Court to prevent Sun Pharmaceutical Industries from launching its generic version of semaglutide, a key ingredient in its popular weight-loss drugs. This move comes as the patent for semaglutide is set to expire in India in March 2026. The case is being transferred to a bench already handling similar litigation by Novo Nordisk against Dr Reddy's Laboratories and Natco Pharma.

https://www.livemint.com/companies/news/novo-nordisk-vs-sun-pharma-semaglutide-patent-expiry-india-wegovy-cipla-eli-lily-11765261061980.html

Trending Today

Novo Nordisk A/S Price History

30.09.2025 - NVO Stock was down 5.3%

• Novo Nordisk saw a decrease in its stock price, closing at $52.05, reflecting a -1.59% change from the previous day.
• Investors raised concerns following the company's proposal to acquire Metsera, Inc., impacting sentiment on Novo Nordisk's financials and strategic outlook.
• Eli Lilly's strong market performance in GLP-1s, a key competitive area with Novo Nordisk, may have added to the pessimism surrounding Novo Nordisk's stock.
• The stock's decline could also be attributed to broader market trends, with investors potentially adjusting their portfolios in response to the overall market uptick.

11.10.2025 - NVO Stock was up 7.9%

• Despite losing the bidding war for Metsera Inc to Pfizer, Novo Nordisk's stock rose. Investors may see potential growth prospects for the company even after this setback.
• The company's price reduction for Wegovy in India could indicate a strategic move to expand market reach, boosting investor confidence in Novo Nordisk's growth.
• Uncertainty about Novo Nordisk's short-term outlook due to lower GLP-1 prices for Ozempic and Wegovy may have been outweighed by positive developments or market sentiment, driving the stock's upward movement.
• The impact of Trump's Most Favored Nation (MFN) policy on drug prices, including companies like Novo Nordisk, could have influenced investor sentiment, contributing to the stock's positive performance.

11.10.2025 - NVO Stock was up 5.2%

• The bullish movement in NVO stock could be attributed to the company's announcement of trading activities by board members and executives, which may have instilled confidence in investors.
• The uncertainty surrounding NVO's near-term outlook due to lower GLP-1 prices could have been overshadowed by the positive market sentiment towards the company's strategic decisions.
• Despite losing the bidding war for Metsera to Pfizer, Novo Nordisk's decision not to increase its proposal to acquire the company might have been perceived as a prudent financial move by investors.
• The potential impact of Trump's MFN policy on Pharma ETFs, including NVO, could have been mitigated by other positive developments within the company, leading to the bullish market movement.

25.10.2025 - NVO Stock was up 5.1%

• NVO stock showed strong momentum today despite setbacks in Alzheimer's disease trials.
• Positive phase 2 trial results with amycretin for type 2 diabetes patients likely contributed to investor confidence in Novo Nordisk's future.
• The company's strategic shift towards diabetes treatments, exemplified by successful trial outcomes, may have fueled the bullish market activity.
• Investors demonstrate optimism about Novo Nordisk's growth potential, choosing to focus on its diabetes-related achievements over recent challenges in other therapeutic areas.

25.10.2025 - NVO Stock was up 6.2%

• Positive phase 2 trial results for amycretin in type 2 diabetes patients led to significant weight loss and HbA1c reduction, driving optimism among investors.
• Novo Nordisk's decision to lower self-pay prices for Wegovy and Ozempic in the U.S. has the potential to enhance accessibility and stimulate demand for their products.
• Despite these developments, the stock saw a notable drop in pre-market trading, potentially linked to concerns about Evoke Phase 3 trials not meeting expectations for GLP-1 drugs.

05.10.2025 - NVO Stock was down 5.4%

• Lower-than-anticipated sales figures in the third quarter of 2025 resulted in a decline in Novo Nordisk's stock value.
• Investor apprehension arose following the company's revised growth projections for obesity drugs, prompting concerns about its future revenue in this cutthroat market.
• The escalating competition with Pfizer for the purchase of weight-loss drug manufacturer Metsera Inc. has injected uncertainty and downward pressure on Novo Nordisk's stock, as investors navigate the implications of the heightened bid and the shifting dynamics of the weight loss and diabetes medication segment.
• Amid Novo Nordisk's robust sales expansion in the initial three quarters of 2025 and ongoing advancements in its research and development pipeline, market sentiment appears predominantly influenced by immediate worries surrounding its obesity drug division and the unfolding acquisition saga with Pfizer.

04.10.2025 - NVO Stock was up 2.4%

• Novo Nordisk experienced strong bullish movement following the submission of an updated proposal to acquire Metsera, Inc., which has been considered superior to Pfizer's offer. This reflects market confidence in Novo Nordisk's strategic positioning in the weight-loss drug sector.
• Lawsuits filed by Pfizer to impede Novo Nordisk's bid may have introduced some uncertainty to the market, but investors appear optimistic about Novo Nordisk's potential in the acquisition.
• The impending Q3 earnings report for Novo Nordisk is a key aspect to monitor, considering the company's performance against challenges like slowing momentum for key drugs such as Wegovy and Ozempic, pricing risks, and intense market competition.
• Antitrust accusations by Pfizer against Novo Nordisk in the Metsera takeover battle could lead to stock volatility; however, the current bullish trend suggests investors are prioritizing the potential benefits of the acquisition for Novo Nordisk.

17.09.2025 - NVO Stock was down 5.2%

• NVO's stock price decreased by 1.11% after remarks from a prominent government official about reducing drug prices, with particular emphasis on weight-loss medications.
• The rise in Novo Nordisk's short interest is believed to have played a role in the downward movement, as some investors seem to be anticipating a further drop in the stock price.
• Despite finalizing a significant deal worth $2.1 billion to enhance its rare disease portfolio, concerns about weight-loss drugs and potential pricing restrictions took precedence in the market, resulting in the decline in NVO's stock.

07.10.2025 - NVO Stock was down 6.9%

• Novo Nordisk reached an agreement with the U.S. Administration to enhance patient access to semaglutide and reduce drug prices, potentially impacting short-term revenues adversely.
• Q3 earnings and revenues fell below expectations despite the presentation of new Wegovy dosage benefits at the ObesityWeek. Slower growth for Wegovy and Ozempic resulted from pricing challenges in the U.S.
• Pfizer's unsuccessful attempt to impede Novo Nordisk's bid for Metsera could have introduced market uncertainty, influencing a negative sentiment towards Novo Nordisk's stock.
• The collaboration with Fangzhou for AI-driven chronic disease management solutions could be a positive long-term development. However, market reactions seem more inclined towards recent financial performance and competitive factors.

06.10.2025 - NVO Stock was down 5.2%

• Disappointing Q3 earnings and revenues for Novo Nordisk were driven by the slower growth of its obesity drugs, Wegovy and Ozempic, particularly in the U.S.
• Despite efforts to reduce drug prices and improve patient access, challenges in the pharmaceutical industry may have led to a negative market response.
• Competition, exemplified by Pfizer's unsuccessful attempt to block Novo Nordisk's acquisition of Metsera, likely impacted Novo Nordisk's stock price.
• Novo Nordisk revising its growth forecast for obesity drugs may have raised concerns about future profitability and market performance.

06.10.2025 - NVO Stock was up 4.3%

• Novo Nordisk's higher-dose trial results for Wegovy showcasing weight loss and cardiovascular benefits likely boosted investor confidence in the company's obesity drug portfolio.
• The denial of Pfizer's attempt to block Novo Nordisk's bid for Metsera may have signaled to investors the company's commitment to expanding its offerings and market presence.
• Despite Q3 earnings missing expectations and a trimmed growth outlook for obesity drugs, Novo Nordisk's overall sales growth and progress in its R&D pipeline seem to have reassured investors about the company's long-term prospects.
• The market's positive reaction to Novo Nordisk's announcements today suggests that investors are focusing more on the company's future potential and pipeline progress rather than short-term financial performance.

10.11.2025 - NVO Stock was up 5.1%

• The bullish movement in Novo Nordisk's stock could be linked to the completion of its acquisition of Akero Therapeutics, which is slated to expand its portfolio and potential for growth.
• Investor interest may have been piqued by the reevaluation of NVO's valuation following a significant share price decline earlier this year.
• Encouraging developments concerning Novo Nordisk's key products, such as promising sales projections for Wegovy and progress in amycretin trials, likely bolstered investor confidence in the company's future outlook.
• Novo Nordisk's legal actions to prevent Sun Pharma from introducing a generic version of its weight-loss medication ahead of an impending patent expiration showcases the company's commitment to safeguarding its market share and intellectual property, potentially impacting the bullish market activity.